V
110.15
29.39 (36.39%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vaxcyte, Inc. | Bullish | Bullish |
Stockmoo Score
-0.6
|
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (BTIG, 45.26%) | Buy |
| Median | 140.00 (27.10%) | |
| Low | 129.00 (Jefferies, 17.11%) | Buy |
| Average | 144.40 (31.09%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 109.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 04 Sep 2024 | 140.00 (27.10%) | Buy | 109.15 |
| BTIG | 03 Sep 2024 | 160.00 (45.26%) | Buy | 110.15 |
| Jefferies | 03 Sep 2024 | 129.00 (17.11%) | Buy | 110.15 |
| Leerink Partners | 03 Sep 2024 | 153.00 (38.90%) | Buy | 110.15 |
| Needham | 03 Sep 2024 | 140.00 (27.10%) | Buy | 110.15 |
| 28 Jun 2024 | 95.00 (-13.75%) | Buy | 75.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Sep 2024 | Announcement | Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 04 Sep 2024 | Announcement | Vaxcyte Announces Pricing of $1.3 Billion Public Offering |
| 03 Sep 2024 | Announcement | Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older |
| 03 Sep 2024 | Announcement | Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 02 Sep 2024 | Announcement | Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older |
| 06 Aug 2024 | Announcement | Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update |
| 02 Jul 2024 | Announcement | Vaxcyte Appoints John Furey to Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |